Search

Displaying results 1071 - 1080 of 4591 in total
  1. Drug

    Strontium chloride Sr-89

    go.drugbank.com/drugs/DB09498
    Approved

    Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate can...

  2. Drug

    Phendimetrazine

    go.drugbank.com/drugs/DB01579
    ApprovedIllicit

    Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.

  3. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. … [L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.

  4. Drug

    Ampicillin

    go.drugbank.com/drugs/DB00415
    ApprovedInvestigationalVet approved

    Ampicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.

    Mixtures: Ampicillin/Sulbactam Astro 3 g Pulver zur Herstellung einer Injektions- oder Infusionslösung, Ampicillin/Sulbactam Astro 1,5 g Pulver zur Herstellung einer Injektions- oder InfusionslösungProducts: AMPICILINA MK 250 MG CAPSULAS, AMPICILINA MK TABLETAS DE 250 MG
  5. Drug

    BacTRL-spike

    go.drugbank.com/drugs/DB15811
    Investigational

    BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. … The vaccine was developed by Symvivo Corporation.

  6. Drug

    Magaldrate

    go.drugbank.com/drugs/DB08938
    ApprovedInvestigationalWithdrawn

    Magaldrate has been discontinued in the US market.

  7. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    By binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity. … Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma

  8. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by … [A215127, L14897] Although effective, these compounds are rapidly metabolized by cytidine deaminase (CDA) prior to reaching systemic circulation when administered orally, necessitating intramuscular or

  9. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013 … Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.[L12162]

  10. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]